Filtered By:
Specialty: Cardiology
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 478 results found since Jan 2013.

Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants
This article summarizes phase III data in patient subtypes and discusses controversies surrounding AF management with these agents. Results indicate that NOACs in non-valvular AF have an overall improved efficacy–safety profile compared with warfarin. Significantly fewer fatal bleeding events were observed in patients randomized to rivaroxaban, apixaban, or edoxaban compared with those on warfarin, and significant reductions in the incidence of life-threatening bleeding were observed in patients randomized to dabigatran. All four pivotal trials testing the NOACs against warfarin showed significantly lower rates of intrac...
Source: Cardiovascular Drugs and Therapy - January 18, 2016 Category: Cardiology Source Type: research

Safety and efficacy of contemporary catheter ablation for atrial fibrillation patients with a history of cardioembolic stroke in the era of direct oral anticoagulants.
CONCLUSION: The safety and efficacy of CF-guided AF ablation in the era of direct oral anticoagulants in patients with a recent or previous history of CS or TIA are similar to those in patients without it. PMID: 27816321 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - November 1, 2016 Category: Cardiology Authors: Nishizaki K, Itoh T, Kimura M, Tsushima Y, Shoji Y, Kinjo T, Ishida Y, Sasaki K, Horiuchi D, Sasaki S, Tomita H, Okumura K Tags: J Cardiol Source Type: research

Pilot of a Computerised Antithrombotic Risk Assessment Tool Version 2 (CARATV2.0) for stroke prevention in atrial fibrillation.
CONCLUSIONS: This decision support tool can help optimise the use of antithrombotic therapy in patients with AF by considering risk versus benefit profiles and rationalising treatment selection. PMID: 28070883 [PubMed - as supplied by publisher]
Source: Cardiology Journal - January 9, 2017 Category: Cardiology Authors: Wang Y, Bajorek B Tags: Cardiol J Source Type: research

The gap between indicated and prescribed stroke prevention therapies in a high-risk geriatric population
ConclusionsThis data set suggests that 37% of eligible elderly LTC residents failed to receive recommended stroke prevention therapies.
Source: Journal of Interventional Cardiac Electrophysiology - January 15, 2017 Category: Cardiology Source Type: research

Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
CONCLUSIONS: Non-persistence (treatment discontinuation or switch) with vitamin K antagonists was lower than with rivaroxaban and dabigatran in French primary care; however, non-persistence with the newest drug, apixaban, was similar to vitamin K antagonists. Larger studies with longer follow-up are needed to support these findings. This study is registered on ClinicalTrials.gov (NCT02488421). PMID: 29398546 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - February 2, 2018 Category: Cardiology Authors: Collings SL, Vannier-Moreau V, Johnson ME, Stynes G, Lefèvre C, Maguire A, Asmar J, Bizouard G, Duhot D, Mouquet F, Fauchier L Tags: Arch Cardiovasc Dis Source Type: research

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after PCI: An ancillary analysis from the RE-DUAL PCI trial
ConclusionDabigatran dual therapy reduced bleeding events irrespective of bleeding risk category and demonstrated similar efficacy regardless of stroke risk category when compared with warfarin triple therapy.
Source: American Heart Journal - March 4, 2019 Category: Cardiology Source Type: research

Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
CONCLUSIONS: Initiation of apixaban versus NOACs was more common among patients with increased age, higher bleeding risk and decreased renal function, whereas initiation of apixaban versus VKAs was more common among patients with lower bleeding risk and better renal function. PMID: 31014991 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - April 19, 2019 Category: Cardiology Authors: Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy FX, Ricci L, Steg PG Tags: Arch Cardiovasc Dis Source Type: research

Management of Patients with Embolic Stroke of Unknown Source: Interpreting the Evidence in the Light of Clinical Judgement
Curr Neurol Neurosci Rep. 2022 May 7. doi: 10.1007/s11910-022-01202-w. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: To assess the validity of the belief that anticoagulation is not beneficial in patients with embolic stroke of unknown source (ESUS), and to asssess the benefits and safety of direct-acting oral anticoagulants (DOACs).RECENT FINDINGS: The failure of randomized trials to show benefit of anticoagulation in ESUS is probably due to misclassification of large artery atherosclerosis (LAA) as ESUS, as defined by a stenosis ≥ 50%. There are important differences among DOACs. There are a number of problems with ...
Source: Atherosclerosis - May 7, 2022 Category: Cardiology Authors: J David Spence Source Type: research

Renal function, P-gp-affecting drugs and new anticoagulants for stroke prevention
New oral anticoagulants (NOAs), like the thrombin-inhibitor dabigatran etexilate or the factor Xa-inhibitor rivaroxaban showed similar efficacy as the vitamin-K-antagonist (VKA) warfarin for stroke prevention in patients with atrial fibrillation (AF) . One of the advantages of the NOAs, compared with VKAs, should be the lack of the necessity for laboratory monitoring and its lower rate of drug- and food interactions. The serum concentration of NOAs, however, is influenced by renal function. Furthermore, NOA-absorption is dependent on the intestinal P-glycoprotein (P-gp)-system, and P-gp activity is influenced by several dr...
Source: International Journal of Cardiology - February 11, 2013 Category: Cardiology Authors: Florian Höllerl, Claudia Stöllberger, Josef Finsterer Tags: Letters to the Editor Source Type: research

Abstract 242: Healthcare Resource Utilization and Costs among Patients with Non-Valvular Atrial Fibrillation using Dabigatran or Warfarin For Stroke Prevention Session Title: Poster Session II
Conclusions: Although newly diagnosed, newly treated NVAF patients initiated on dabigatran had higher pharmacy costs than those on warfarin, the total healthcare costs were similar between the two cohorts. In addition, fewer office visits were observed in the dabigatran cohort.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Fu, A.-C., Jain, R., Sander, S. D., Lim, J., Jain, G., Yu, Y., Tan, H. Tags: Session Title: Poster Session II Source Type: research

Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Abstract: The availability of 4 non–vitamin K oral anticoagulants (NOACs), that is, dabigatran, rivaroxaban, apixaban, and edoxaban, has changed the landscape of stroke prevention in patients with atrial fibrillation. This review article provides an overview of the 4 phase III studies that have compared these NOACs, examining major outcomes of efficacy and safety. A range of practical questions relating to the NOACs have emerged, including topics such as patient selection, treating patients with renal impairment, treating elderly patients, and combining anticoagulant therapy with antiplatelet drugs. We also address the i...
Source: Current Problems in Cardiology - July 21, 2014 Category: Cardiology Authors: Keitaro Senoo, Deirdre A. Lane, Gregory Y.H. Lip Source Type: research

Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
Conclusions Apixaban, rivaroxaban, and dabigatran are cost-effective alternatives to coumarin derivatives in the UK, while in the Netherlands, only apixaban and dabigatran could be considered cost effective. The cost effectiveness of the new oral anticoagulants is largely dependent on the setting and quality of local anticoagulant care facilities.
Source: American Journal of Cardiovascular Drugs - October 18, 2014 Category: Cardiology Source Type: research

Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk
Atrial fibrillation (AF) is associated with a 5-fold greater risk of ischemic stroke or systemic embolism compared with normal sinus rhythm. Cardioembolic AF-related strokes are often more severe, fatal or associated with greater permanent disability and higher recurrence rates than strokes of other aetiologies. These strokes may be effectively prevented with oral anticoagulant (OAC) therapy, using either vitamin K antagonists (VKAs) or non-vitamin K antagonist oral OACs (NOACs) such as the direct thrombin inhibitor dabigatran or direct factor Xa inhibitors rivaroxaban, apixaban or edoxaban.
Source: Progress in Cardiovascular Diseases - July 7, 2015 Category: Cardiology Authors: Tatjana S. Potpara, Gregory Y.H. Lip Tags: Invited Review Source Type: research